Literature DB >> 15264435

Technology evaluation: abatacept, Bristol-Myers Squibb.

Francis J Dumont1.   

Abstract

Bristol-Myers Squibb is developing the fusion protein abatacept for the potential treatment of various immunological disorders, including rheumatoid arthritis, multiple sclerosis and systemic lupus erythematosus. Abatacept is undergoing phase III clinical trials.

Entities:  

Mesh：

Substances：

Year:  2004        PMID： 15264435

Source DB:  PubMed          Journal:  Curr Opin Mol Ther        ISSN： 1464-8431


  6 in total

Review 1.  Guidelines for the use of conventional and newer disease-modifying antirheumatic drugs in elderly patients with rheumatoid arthritis.

Authors:  Alejandro Díaz-Borjón
Journal:  Drugs Aging       Date:  2009       Impact factor: 3.923

2.  Abatacept: the evidence for its place in the treatment of rheumatoid arthritis.

Authors:  Marcus D Köller
Journal:  Core Evid       Date:  2008-02-29

3.  Improved Immunological Tolerance Following Combination Therapy with CTLA-4/Ig and AAV-Mediated PD-L1/2 Muscle Gene Transfer.

Authors:  Sahil Adriouch; Emilie Franck; Laurent Drouot; Carole Bonneau; Nelly Jolinon; Anna Salvetti; Olivier Boyer
Journal:  Front Microbiol       Date:  2011-09-29       Impact factor: 5.640

4.  Safety and efficacy of abatacept in patients with treatment-resistant SARCoidosis (ABASARC) - protocol for a multi-center, single-arm phase IIa trial.

Authors:  Björn C Frye; Ina Caroline Rump; Annette Uhlmann; Fabian Schubach; Gabriele Ihorst; Bodo Grimbacher; Gernot Zissel; Joachim Müller Quernheim
Journal:  Contemp Clin Trials Commun       Date:  2020-05-29

5.  Engineered immunomodulatory accessory cells improve experimental allogeneic islet transplantation without immunosuppression.

Authors:  Xi Wang; Kai Wang; Ming Yu; Diana Velluto; Xuechong Hong; Bo Wang; Alan Chiu; Juan M Melero-Martin; Alice A Tomei; Minglin Ma
Journal:  Sci Adv       Date:  2022-07-22       Impact factor: 14.957

6.  CD86 is an activation receptor for NK cell cytotoxicity against tumor cells.

Authors:  Yanmeng Peng; Gaoxing Luo; Junyi Zhou; Xiaojuan Wang; Jie Hu; Yanyan Cui; Xian C Li; Jianglin Tan; Sisi Yang; Rixing Zhan; Junjie Yang; Weifeng He; Jun Wu
Journal:  PLoS One       Date:  2013-12-11       Impact factor: 3.240
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.